{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T07:07:35Z","timestamp":1771657655698,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,18]]},"DOI":"10.7759\/cureus.21376","type":"journal-article","created":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T16:52:52Z","timestamp":1642524772000},"source":"Crossref","is-referenced-by-count":17,"title":["Analysis of Neurological Adverse Events Reported in VigiBase From COVID-19 Vaccines"],"prefix":"10.7759","author":[{"given":"Siddhartha","family":"Dutta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rimplejeet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaykaran","family":"Charan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pankaj","family":"Bhardwaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sneha R","family":"Ambwani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoban","family":"Babu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jagdish P","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mainul","family":"Haque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"WHO coronavirus disease (COVID-19) dashboard. (2021). Accessed. December 15, 2021: https:\/\/covid19.who.int\/."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S285446","article-title":"Household transmission of COVID-19: a cross-sectional study","volume":"13","author":"Dutta S","year":"2020","unstructured":"Dutta S, Kaur RJ, Bhardwaj P, et al.. Household transmission of COVID-19: a cross-sectional study. Infect Drug Resist. 2020, 13:4637-42. 10.2147\/IDR.S285446","journal-title":"Infect Drug Resist"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2020.585832","article-title":"Rapid assessment of price instability and paucity of medicines and protection for COVID-19 across Asia: findings and public health implications for the future","volume":"8","author":"Godman B","year":"2020","unstructured":"Godman B, Haque M, Islam S, et al.. Rapid assessment of price instability and paucity of medicines and protection for COVID-19 across Asia: findings and public health implications for the future. Front Public Health. 2020, 8:585832. 10.3389\/fpubh.2020.585832","journal-title":"Front Public Health"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.582154","article-title":"Utilisation, availability and price changes of medicines and protection equipment for COVID-19 among selected regions in India: fndings and implications","volume":"11","author":"Haque M","year":"2020","unstructured":"Haque M, Kumar S, Charan J, et al.. Utilisation, availability and price changes of medicines and protection equipment for COVID-19 among selected regions in India: fndings and implications. Front Pharmacol. 2020, 11:582154. 10.3389\/fphar.2020.582154","journal-title":"Front Pharmacol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007%2Fs12291-020-00931-4","article-title":"Use of complementary and alternative medicine (CAM) and home remedies by COVID-19 patients: a telephonic survey","volume":"36","author":"Charan J","year":"2021","unstructured":"Charan J, Bhardwaj P, Dutta S, et al.. Use of complementary and alternative medicine (CAM) and home remedies by COVID-19 patients: a telephonic survey. Indian J Clin Biochem. 2021, 36:108-11. 10.1007%2Fs12291-020-00931-4","journal-title":"Indian J Clin Biochem"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2021.1946513","article-title":"Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database","volume":"20","author":"Charan J","year":"2021","unstructured":"Charan J, Dutta S, Kaur R, et al.. Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database. Expert Opin Drug Saf. 2021, 20:1125-36. 10.1080\/14740338.2021.1946513","journal-title":"Expert Opin Drug Saf"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3329\/bjms.v20i4.54150","article-title":"Hydroxychloroquine as therapeutic option in COVID- 19: analysis of suspected cardiovascular adverse drug events reported in the VigiBase","volume":"6","author":"Dutta S","year":"2021","unstructured":"Dutta S, Kaur R, Bhardwaj P, et al.. Hydroxychloroquine as therapeutic option in COVID- 19: analysis of suspected cardiovascular adverse drug events reported in the VigiBase. Bangladesh J Med Sci. 2021, 6:897-910. 10.3329\/bjms.v20i4.54150","journal-title":"Bangladesh J Med Sci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S307333","article-title":"Fat-soluble vitamins and the current global pandemic of COVID-19: evidence-based efficacy from literature review","volume":"19","author":"Samad N","year":"2021","unstructured":"Samad N, Dutta S, Sodunke TE, et al.. Fat-soluble vitamins and the current global pandemic of COVID-19: evidence-based efficacy from literature review. J Inflamm Res. 2021, 19:2091-110. 10.2147\/JIR.S307333","journal-title":"J Inflamm Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S295377","article-title":"The implications of zinc therapy in combating the COVID-19 global pandemic","volume":"14","author":"Samad N","year":"2021","unstructured":"Samad N, Sodunke TE, Abubakar AR, et al.. The implications of zinc therapy in combating the COVID-19 global pandemic. J Inflamm Res. 2021, 14:527-50. 10.2147\/JIR.S295377","journal-title":"J Inflamm Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S287934","article-title":"Favipiravir use in COVID-19: analysis of suspected adverse drug events reported in the WHO database","volume":"13","author":"Kaur RJ","year":"2020","unstructured":"Kaur RJ, Charan J, Dutta S, et al.. Favipiravir use in COVID-19: analysis of suspected adverse drug events reported in the WHO database. Infect Drug Resist. 2020, 13:4427-38. 10.2147\/IDR.S287934","journal-title":"Infect Drug Resist"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2021.1856655","article-title":"Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications","volume":"14","author":"Charan J","year":"2021","unstructured":"Charan J, Kaur RJ, Bhardwaj P, Haque M, Sharma P, Misra S, Godman B. Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications. Expert Rev Clin Pharmacol. 2021, 14:95-103. 10.1080\/17512433.2021.1856655","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s42399-020-00485-9","article-title":"A review on current repurposing drugs for the treatment of COVID-19: reality and challenges","author":"Hossen MS","year":"2020","unstructured":"Hossen MS, Barek MA, Jahan N, Safiqul Islam M. A review on current repurposing drugs for the treatment of COVID-19: reality and challenges. SN Compr Clin Med. 2020, 1-13. 10.1007\/s42399-020-00485-9","journal-title":"SN Compr Clin Med"},{"key":"ref13","unstructured":"Regulatory Focus.COVID-19 vaccine tracker: Regulatory Affairs Professionals Society (RAPS). (2021). Accessed: March 25, 2021: https:\/\/www.raps.org\/news-and-articles\/news-articles\/2020\/3\/covid-19-vaccine-tracker."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s12291-021-00968-z","article-title":"Adverse events reported from COVID-19 vaccine trials: a systematic review","author":"Kaur RJ","year":"2021","unstructured":"Kaur RJ, Dutta S, Bhardwaj P, et al.. Adverse events reported from COVID-19 vaccine trials: a systematic review. Indian J Clin Biochem. 2021, 1-13. 10.1007\/s12291-021-00968-z","journal-title":"Indian J Clin Biochem"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov DY","year":"2021","unstructured":"Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al.. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021, 397:671-81. 10.1016\/S0140-6736(21)00234-8","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2036242","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"384","author":"Vergnes JN","year":"2021","unstructured":"Vergnes JN. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2021, 384:1577. 10.1056\/NEJMc2036242","journal-title":"N Engl J Med"},{"key":"ref17","unstructured":"COVID vaccine 'side effect' or functional neurological disorder?. (2021). Accessed. May 2, 2021: https:\/\/www.medscape.com\/viewarticle\/949294."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.1042","article-title":"Helping the public understand adverse events associated with COVID-19 vaccinations: lessons learned from functional neurological disorder","volume":"78","author":"Kim DD","year":"2021","unstructured":"Kim DD, Kung CS, Perez DL. Helping the public understand adverse events associated with COVID-19 vaccinations: lessons learned from functional neurological disorder. JAMA Neurol. 2021, 78:789-90. 10.1001\/jamaneurol.2021.1042","journal-title":"JAMA Neurol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/ane.13417","article-title":"The potential neurological effect of the COVID-19 vaccines: a review","volume":"144","author":"Lu L","year":"2021","unstructured":"Lu L, Xiong W, Mu J, et al.. The potential neurological effect of the COVID-19 vaccines: a review. Acta Neurol Scand. 2021, 144:3-12. 10.1111\/ane.13417","journal-title":"Acta Neurol Scand"},{"key":"ref20","unstructured":"Uppsala Monitoring Centre. WHO Programme for International Drug Monitoring. (2020). Accessed: May 10, 2021: https:\/\/www.who-umc.org\/vigibase\/vigibase\/."},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.7324\/JAPS.2021.110801","article-title":"Adverse events reported from the COVID-19 vaccines: a descriptive study based on the WHO database (VigiBase\u00ae)","volume":"11","author":"Dutta S","year":"2021","unstructured":"Dutta S, Kaur R, Bhardwaj P, et al.. Adverse events reported from the COVID-19 vaccines: a descriptive study based on the WHO database (VigiBase\u00ae). J Appl Pharm Sci. 2021, 11:1-9. 10.7324\/JAPS.2021.110801","journal-title":"J Appl Pharm Sci"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S324349","article-title":"Cardiovascular adverse events reported from COVID-19 vaccines: a study based on WHO database","volume":"14","author":"Jeet Kaur R","year":"2021","unstructured":"Jeet Kaur R, Dutta S, Charan J, et al.. Cardiovascular adverse events reported from COVID-19 vaccines: a study based on WHO database. Int J Gen Med. 2021, 14:3909-27. 10.2147\/IJGM.S324349","journal-title":"Int J Gen Med"},{"key":"ref23","unstructured":"Uppsala Monitoring Centre. WHO Programme for International Drug Monitoring. VigiBase FAQs. (202020217). https:\/\/www.who-umc.org\/vigibase\/vigibase\/know-more-about-vigibase\/."},{"key":"ref24","unstructured":"VigiBase. signalling harm and pointing to safer use. (2020). Accessed: May 10, 2020: https:\/\/www.who-umc.org\/vigibase\/vigibase\/vigibase-signalling-harm-and-pointing-to-safer-use\/."},{"key":"ref25","unstructured":"WHO collaborating centre for drug statistics methodology. (2020). Accessed. May 12, 2021: https:\/\/www.whocc.no\/."},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown EG","year":"1999","unstructured":"Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999, 20:109-17. 10.2165\/00002018-199920020-00002","journal-title":"Drug Saf"},{"key":"ref27","unstructured":"ICH Harmonised Tripartite Guideline Maintenance Of The Ich Guideline On Clinical Safety Data Management .Data Elements For Transmission Of Individual Case Safety Reports E2B(R2) [cited. (20219). https:\/\/admin.ich.org\/sites\/default\/files\/inline-files\/E2B_R2_Guideline.pdf."},{"key":"ref28","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Medical Dictionary for Regulatory Activities(MedDRA). (2020202114). https.\/\/www.meddra.org\/how-to-use\/support-documentation\/english\/welcome."},{"key":"ref29","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (2020). Accessed. May 15, 2020: https:\/\/www.meddra.org\/how-to-use\/basics\/hierarchy."},{"key":"ref30","unstructured":"Glossary of pharmacovigilance terms. (2020). Accessed. May 14, 2020: https:\/\/www.who-umc.org\/global-pharmacovigilance\/publications\/glossary\/."},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate A","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, De Freitas RM. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998, 54:315-21. 10.1007\/s002280050466","journal-title":"Eur J Clin Pharmacol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database","volume":"72","author":"Montastruc JL","year":"2011","unstructured":"Montastruc JL, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011, 72:905-8. 10.1111\/j.1365-2125.2011.04037.x","journal-title":"Br J Clin Pharmacol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1601","article-title":"A comparison of measures of disproportionality for signal detection on adverse drug reaction spontaneous reporting database of Guangdong province in China","volume":"17","author":"Li C","year":"2008","unstructured":"Li C, Xia J, Deng J, Jiang J. A comparison of measures of disproportionality for signal detection on adverse drug reaction spontaneous reporting database of Guangdong province in China. Pharmacoepidemiol Drug Saf. 2008, 17:593-600. 10.1002\/pds.1601","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2012.50","article-title":"Novel data-mining methodologies for adverse drug event discovery and analysis","volume":"91","author":"Harpaz R","year":"2012","unstructured":"Harpaz R, DuMouchel W, Shah NH, Madigan D, Ryan P, Friedman C. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin Pharmacol Ther. 2012, 91:1010-21. 10.1038\/clpt.2012.50","journal-title":"Clin Pharmacol Ther"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate A","year":"2009","unstructured":"Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009, 18:427-36. 10.1002\/pds.1742","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202102_24877","article-title":"COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer\/BioNTech and Moderna vaccines","volume":"25","author":"Meo SA","year":"2021","unstructured":"Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer\/BioNTech and Moderna vaccines. Eur Rev Med Pharmacol Sci. 2021, 25:1663-9. 10.26355\/eurrev_202102_24877","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref37","unstructured":"Food and Drug Administration. Fact Sheet for healthcare providers administering vaccine emergency use authorization (EUA) of The Pfizer-BioNTech COVID-19 vaccine to prevent coronavirus disease 2019. (2021). Accessed. May 22, 2021: https:\/\/www.fda.gov\/media\/144413\/download."},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden LR","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B, et al.. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021, 384:403-16. 10.1056\/NEJMoa2035389","journal-title":"N Engl J Med"},{"key":"ref39","unstructured":"Food and Drug Administration. Fact sheet for healthcare providers administering vaccine (vaccination providers) emergency use authorization (EUA) of the Moderna Covid-19 vaccine to prevent coronavirus disease 2019. (2021). Accessed. May 22, 2021: https:\/\/www.fda.gov\/media\/144637\/download."},{"key":"ref40","unstructured":"Medicines & Healthcare products Regulatory Agency. Information for UK recipients on COVID 19 vaccine AstraZeneca. (2021). Accessed. March 9, 2021: https:\/\/www.gov.uk\/government\/publications\/regulatory-approval-of-covid-19-vaccine-astrazeneca\/information-for-uk-rec...."},{"key":"ref41","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.86.16_supplement.P1.147","article-title":"Post-vaccination headache reporting trends according to the vaccine adverse events reporting system (VAERS) (P1.147)","volume":"86","author":"Cocores A","year":"2016","unstructured":"Cocores A, Monteith T. Post-vaccination headache reporting trends according to the vaccine adverse events reporting system (VAERS) (P1.147). Neurology. 2016, 86:1-147.","journal-title":"Neurology"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy MN","year":"2021","unstructured":"Ramasamy MN, Minassian AM, Ewer KJ, et al.. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial. Lancet. 2021, 396:1979-93. 10.1016\/S0140-6736(20)32466-1","journal-title":"Lancet"},{"key":"ref43","unstructured":"Centers for Disease Control and Prevention. COVID-19 vaccine safety update: Advisory Committee on Immunization Practices (ACIP) CDC COVID-19 Vaccine Task Force; March 1, 2021. (2021). Accessed: May 25, 2021: https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2021-02\/28-03-01\/05-covid-Shimabukuro.pdf."},{"key":"ref44","unstructured":"Centers for Disease Control and Prevention. COVID-19 vaccine safety update: Advisory Committee on Immunization Practices (ACIP) June 23, 2021. (2021). Accessed: December 28, 2021: https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2021-06\/03-COVID-Shimabukuro-508.pdf."},{"key":"ref45","article-title":"First month of COVID-19 vaccine safety monitoring \u2014 United States, December 14, 2020-January 13, 2021","volume":"70","author":"Gee J","year":"2021","unstructured":"Gee J, Marquez P, Su J, et al.. First month of COVID-19 vaccine safety monitoring \u2014 United States, December 14, 2020-January 13, 2021. MMWR Morb Mortal Wkly Rep. 2021, 70:283-8.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-019-0132-6","article-title":"The how's and what's of vaccine reactogenicity","volume":"4","author":"Herv\u00e9 C","year":"2019","unstructured":"Herv\u00e9 C, Laup\u00e8ze B, Del Giudice G, Didierlaurent AM, Da Silva FT. The how's and what's of vaccine reactogenicity. NPJ Vaccines. 2019, 4:39. 10.1038\/s41541-019-0132-6","journal-title":"NPJ Vaccines"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00943","article-title":"Different adjuvants induce common innate pathways that are associated with enhanced adaptive responses against a model antigen in humans","volume":"8","author":"Burny W","year":"2017","unstructured":"Burny W, Callegaro A, Bechtold V, et al.. Different adjuvants induce common innate pathways that are associated with enhanced adaptive responses against a model antigen in humans. Front Immunol. 2017, 8:943. 10.3389\/fimmu.2017.00943","journal-title":"Front Immunol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9010065","article-title":"Nanomaterial delivery systems for mRNA vaccines","volume":"9","author":"Buschmann MD","year":"2021","unstructured":"Buschmann MD, Carrasco MJ, Alishetty S, Paige M, Alameh MG, Weissman D. Nanomaterial delivery systems for mRNA vaccines. Vaccines (Basel). 2021, 9:65. 10.3390\/vaccines9010065","journal-title":"Vaccines (Basel)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/79628-analysis-of-neurological-adverse-events-reported-in-vigibase-from-covid-19-vaccines","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T14:56:10Z","timestamp":1726498570000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/79628-analysis-of-neurological-adverse-events-reported-in-vigibase-from-covid-19-vaccines"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,18]]},"references-count":48,"URL":"https:\/\/doi.org\/10.7759\/cureus.21376","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1,18]]}}}